Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price traded up 11.3% on Friday . The stock traded as high as $11.98 and last traded at $11.79. 208,645 shares were traded during mid-day trading, a decline of 27% from the average session volume of 286,000 shares. The stock had previously closed at $10.59.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. Leerink Partnrs raised shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Leerink Partners assumed coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price target for the company. Finally, Guggenheim reissued a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Maze Therapeutics currently has a consensus rating of "Buy" and an average target price of $25.67.
Check Out Our Latest Report on MAZE
Maze Therapeutics Stock Up 3.9 %
The firm has a 50 day simple moving average of $9.98.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($18.32) EPS for the quarter, missing analysts' consensus estimates of ($7.60) by ($10.72).
Institutional Trading of Maze Therapeutics
Institutional investors have recently made changes to their positions in the business. Alphabet Inc. purchased a new position in shares of Maze Therapeutics in the 1st quarter worth $26,561,000. General Catalyst Group Management LLC bought a new position in shares of Maze Therapeutics during the 1st quarter valued at approximately $11,405,000. Bessemer Group Inc. purchased a new stake in Maze Therapeutics during the 1st quarter valued at $5,305,000. Bank of New York Mellon Corp bought a new stake in Maze Therapeutics in the first quarter worth $190,000. Finally, New York State Common Retirement Fund purchased a new position in Maze Therapeutics during the first quarter worth $25,000.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Read More
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
